CryoPort (CYRX)
Market Price (12/18/2025): $9.3 | Market Cap: $466.2 MilSector: Industrials | Industry: Air Freight & Logistics
CryoPort (CYRX)
Market Price (12/18/2025): $9.3Market Cap: $466.2 MilSector: IndustrialsIndustry: Air Freight & Logistics
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 14%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 10% | Weak multi-year price returns2Y Excs Rtn is -85%, 3Y Excs Rtn is -114% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -51 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -21% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -40% | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.1%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14% | |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 41% | Key risksCYRX key risks include [1] severe financial underperformance, Show more. | |
| Megatrend and thematic driversMegatrends include Advanced Biologics Supply Chain. Themes include Cell and Gene Therapy Logistics, Cryogenic Cold Chain Management, and Biopharmaceutical Clinical Trial Support. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 14%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 10% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -40% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 41% |
| Megatrend and thematic driversMegatrends include Advanced Biologics Supply Chain. Themes include Cell and Gene Therapy Logistics, Cryogenic Cold Chain Management, and Biopharmaceutical Clinical Trial Support. |
| Weak multi-year price returns2Y Excs Rtn is -85%, 3Y Excs Rtn is -114% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -51 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -21% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -6.1%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14% |
| Key risksCYRX key risks include [1] severe financial underperformance, Show more. |
Valuation, Metrics & Events
CYRX Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Here are five key points explaining CryoPort's (CYRX) stock movement from August 31, 2025, to December 18, 2025:
1. Strong Q3 2025 Financial Results.
Cryoport announced impressive third-quarter 2025 financial results on November 4, 2025, with revenue increasing 15% year-over-year to $44.2 million, surpassing analyst expectations. The company also updated its full-year 2025 revenue guidance to $170-$174 million.
2. Improved Profitability and Margins.
The company demonstrated a clear path to profitability, reporting an adjusted EBITDA loss of $0.6 million for Q3 2025, a significant improvement from a $2.7 million loss in Q3 2024. Cryoport also maintained a solid gross margin of 48% and aims for positive adjusted EBITDA by year-end 2025 or early 2026.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CYRX Return | 167% | 35% | -71% | -11% | -50% | 19% | -44% |
| Peers Return | 87% | 33% | -35% | 4% | 11% | -2% | 83% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 14% | 108% |
Monthly Win Rates [3] | |||||||
| CYRX Win Rate | 67% | 50% | 42% | 33% | 50% | 50% | |
| Peers Win Rate | 65% | 58% | 37% | 50% | 45% | 53% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| CYRX Max Drawdown | -18% | 0% | -73% | -47% | -64% | -40% | |
| Peers Max Drawdown | -40% | -9% | -48% | -31% | -21% | -32% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: AZTA, BLFS, TMO, GTLS, RGEN. See CYRX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/17/2025 (YTD)
How Low Can It Go
| Event | CYRX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -89.0% | -25.4% |
| % Gain to Breakeven | 808.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -31.4% | -33.9% |
| % Gain to Breakeven | 45.8% | 51.3% |
| Time to Breakeven | 44 days | 148 days |
| 2018 Correction | ||
| % Loss | -48.6% | -19.8% |
| % Gain to Breakeven | 94.5% | 24.7% |
| Time to Breakeven | 71 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -75.9% | -56.8% |
| % Gain to Breakeven | 315.2% | 131.3% |
| Time to Breakeven | 371 days | 1,480 days |
Compare to LIN, ALKS, LIVN, PCRX, ELOG
In The Past
CryoPort's stock fell -89.0% during the 2022 Inflation Shock from a high on 11/4/2021. A -89.0% loss requires a 808.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select past ideas related to CYRX. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11212025 | CNM | Core & Main | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.8% | 19.8% | -1.6% |
| 11212025 | VRRM | Verra Mobility | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 2.2% | 2.2% | -1.2% |
| 11212025 | LII | Lennox International | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 5.9% | 5.9% | 0.0% |
| 11212025 | ADP | Automatic Data Processing | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 4.2% | 4.2% | -1.2% |
| 11212025 | CW | Curtiss-Wright | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.5% | 1.5% | 0.0% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11212025 | CNM | Core & Main | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.8% | 19.8% | -1.6% |
| 11212025 | VRRM | Verra Mobility | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 2.2% | 2.2% | -1.2% |
| 11212025 | LII | Lennox International | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 5.9% | 5.9% | 0.0% |
| 11212025 | ADP | Automatic Data Processing | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 4.2% | 4.2% | -1.2% |
| 11212025 | CW | Curtiss-Wright | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.5% | 1.5% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for CryoPort
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 95.74 |
| Mkt Cap | 5.1 |
| Rev LTM | 651 |
| Op Inc LTM | -14 |
| FCF LTM | 71 |
| FCF 3Y Avg | 58 |
| CFO LTM | 102 |
| CFO 3Y Avg | 95 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.6% |
| Rev Chg 3Y Avg | 3.7% |
| Rev Chg Q | 10.3% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Mgn LTM | -2.4% |
| Op Mgn 3Y Avg | -2.4% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | 14.5% |
| CFO/Rev 3Y Avg | 7.4% |
| FCF/Rev LTM | 9.9% |
| FCF/Rev 3Y Avg | 2.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 5.1 |
| P/S | 3.2 |
| P/EBIT | 21.7 |
| P/E | 17.5 |
| P/CFO | 21.3 |
| Total Yield | 0.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.3% |
| D/E | 0.2 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.7% |
| 3M Rtn | 9.3% |
| 6M Rtn | 35.5% |
| 12M Rtn | 1.9% |
| 3Y Rtn | 0.5% |
| 1M Excs Rtn | 4.0% |
| 3M Excs Rtn | 5.7% |
| 6M Excs Rtn | 23.1% |
| 12M Excs Rtn | -9.0% |
| 3Y Excs Rtn | -71.4% |
Comparison Analyses
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/4/2025 | -7.5% | -4.0% | 3.5% |
| 8/6/2025 | -6.3% | 3.8% | 18.3% |
| 3/4/2025 | 30.6% | 31.4% | 21.7% |
| 11/7/2024 | -3.6% | -8.0% | 3.9% |
| 8/6/2024 | -0.3% | 5.3% | 5.4% |
| 3/12/2024 | -11.9% | 1.5% | 10.8% |
| 11/8/2023 | 10.0% | 29.5% | 48.3% |
| 8/9/2023 | -1.8% | -4.6% | -6.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 11 |
| # Negative | 11 | 10 | 10 |
| Median Positive | 7.7% | 5.3% | 10.8% |
| Median Negative | -3.6% | -7.4% | -7.9% |
| Max Positive | 30.6% | 39.4% | 54.9% |
| Max Negative | -32.0% | -24.1% | -31.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11062025 | 10-Q 9/30/2025 |
| 6302025 | 8122025 | 10-Q 6/30/2025 |
| 3312025 | 5082025 | 10-Q 3/31/2025 |
| 12312024 | 3072025 | 10-K 12/31/2024 |
| 9302024 | 11072024 | 10-Q 9/30/2024 |
| 6302024 | 8082024 | 10-Q 6/30/2024 |
| 3312024 | 5082024 | 10-Q 3/31/2024 |
| 12312023 | 3132024 | 10-K 12/31/2023 |
| 9302023 | 11092023 | 10-Q 9/30/2023 |
| 6302023 | 8092023 | 10-Q 6/30/2023 |
| 3312023 | 5042023 | 10-Q 3/31/2023 |
| 12312022 | 2282023 | 10-K 12/31/2022 |
| 9302022 | 11042022 | 10-Q 9/30/2022 |
| 6302022 | 8042022 | 10-Q 6/30/2022 |
| 3312022 | 5052022 | 10-Q 3/31/2022 |
| 12312021 | 2282022 | 10-K 12/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |